Oxyalkylene phosphate compounds and uses thereof

Details Oxyalkylene phosphate compounds and uses thereof Oxyalkylene phosphate compounds and uses thereof

1997-03-11

2000-02-29

Raymond, Richard L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

514121, 558179, 558180, 558182, A61K 3166, C07F 909, C07F 9165

Patent

active

06030961&

ABSTRACT:
This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound hearing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, modulating gene expression and in particular, augmenting expression of tumor suppressor genes, inducing tolerance to antigens, treating, preventing or ameliorating protozoan infection, or inhibiting histone deacetylase in cells. The compositions of the invention are to and the methods of the invention use oxyalkalene phosphate compounds.

REFERENCES:
patent: 2940855 (1960-06-01), Beavers et al.
patent: 3219630 (1965-11-01), Sidi
patent: 3293220 (1966-12-01), Minami et al.
patent: 3336262 (1967-08-01), Sidi
patent: 3720706 (1973-03-01), Lapporte et al.
patent: 3812176 (1974-05-01), Lapporte et al.
patent: 3931412 (1976-01-01), Kensler, Jr. et al.
patent: 3980738 (1976-09-01), Arlt et al.
patent: 4012526 (1977-03-01), Kensler, Jr. et al.
patent: 4105681 (1978-08-01), Bollag et al.
patent: 4123552 (1978-10-01), Kensler, Jr. et al.
patent: 4198416 (1980-04-01), Koeda et al.
patent: 4215215 (1980-07-01), Bollag et al.
patent: 4541944 (1985-09-01), Sanderson
patent: 4545784 (1985-10-01), Sanderson
patent: 4613505 (1986-09-01), Mizushima et al.
patent: 4699925 (1987-10-01), Uchida et al.
patent: 4760057 (1988-07-01), Alexander
patent: 4816570 (1989-03-01), Farquhar
patent: 4885311 (1989-12-01), Parish et al.
patent: 4900478 (1990-02-01), Gross
patent: 4916230 (1990-04-01), Alexander
patent: 4968788 (1990-11-01), Farquhar
patent: 5025029 (1991-06-01), Perrine
patent: 5158773 (1992-10-01), Gross
patent: 5185436 (1993-02-01), Villa et al.
patent: 5196567 (1993-03-01), Uchida et al.
patent: 5200553 (1993-04-01), Nudelman et al.
patent: 5216004 (1993-06-01), Perrine
patent: 5569675 (1996-10-01), Rephaeli et al.
patent: 5710176 (1998-01-01), Rephaeli et al.
Nehring, Chemical Abstracts, vol. 66, abstract 18253, 1967.
Srivastva et al., Chemical Abstracts, vol. 113, abstract 152924, 1990.
Farquhar et al., Chemical Abstracts, vol. 122, abstract 10455, 1995.
Farquhar et al., Chemical Abstracts, vol. 122, abstract 133667, 1995.
Casagrande et al., Chemical Abstracts, vol. 105, abstract 97679, 1986.
Bednarski, et al., "Rabbit Muscle Aldolase as a Catalyst in Organic Synthesis", Chem. Abstracts, vol. 110, Abstract 57935c, 1989.
Bhatia, et al., "Induction of Cell Differentiation Potentiates Apoptosis Triggered by Prior Exposure to DNA-damaging Drugs", Cell Growth and Differentiation, vol. 6, pp. 937-944, 1995.
Boffa, et al., "Manifold Effects of Sodium Butyrate on Nuclear Function", J. Biol. Chem., vol. 256, No. 18, pp. 9612-9621, 1981.
Bourgeade, et al., "Reorganization of the Cytoskeleton by Interferon in MSV-Transformed Cells", J. of Interferon Res., vol. 1, No. 2, pp. 323-332, 1981.
Brant and Conklin, "Acrolein Diacylates", Chem. Abstracts, vol. 40, p. 3127, 1946.
Carstea, et al., "Analogues of Butyric Acid that Increase the Expression of Transfected DNAs", Biochem. Biophys. Res. Com., vol. 192, No. 2, pp. 649-656, 1993.
Cheng, et al., "Functional Activation of the Cystic Fibrosis Trafficking Mutant deltaF508-CFTR by Overexpression", American Journal of Physiology, vol. 268, No. 4, pp. L615-L624, 1995.
Conway, et al., "Induction of Apoptosis by Sodium Butyrate in the Human Y-79 Retinoblastoma Cell Line", Oncology Research, vol. 7, No. 6, pp. 289-297, 1995.
de Haan, et al., "Effects of Sodium Butyrate on the Synthesis and Methylation of DNA in Normal Cells and Their Transformed Counterparts", Cancer Res., vol. 46, No. 2, pp. 713-716, 1986.
Farquhar, et al., "Biologically Reversible Phosphate Protective Groups", J. Pharm. Sci., vol. 72, No. 3, pp. 324-325, 1983.
Farquhar, et al., "Synthesis and Antitumor Evaluation of Bis[(pivaloyloxy)methyl]2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells", J. Med. Chem., vol. 37, No. 23, pp. 3902-39009, 1994.
Fishman and Atikkan, "Induction of Cholera Toxin Receptors in Cultured Cells by Butyric Acid", J. Biol. Chem., vol. 254, No. 11, pp. 4342-4344, 1979.
Friis and Bundgaard, "Prodrugs of phosphates and phosphonates: Novel lipophilic alpha-acyloxyalkyl ester derivatives of phosphate- or phosphonate containing drugs masking the negative charges of these groups", Eur. J. Pharm. Sci., vol. 4, pp. 49-59, 1996.
Hague, et al., "Apoptosis in Colorectal Tumor Cells: Induction by the Short Chain Fatty Acids Butyrate, Propionate and Acetate and by the Bile Salt Deoxycholate", Int. J. Cancer, vol. 60, pp. 400-406, 1995.
Ingram and Thomas, "The Electron Impact Induced Fragmentation of Geminal Dialkanoates", Organic Mass Spectrometry, vol. 12, No. 4, pp. 216-221, 1977.
Man, et al., "Boron Fluoride Catalyzed Addition of Aliphatic Anhydrides to Aldehydes", J. Am. Chem. Soc., pp. 847-848, 1950.
Miller, et al., "Clinical Pharmacology of Sodium Butyrate in Patients with Acute Leukemia", Eur. J. Cancder Clin Oncol. vol. 23, No. 9, pp. 1283-1287, 1987.
Mosher and Kehr, "The Oxidation of Aliphatic Esters with Lead Tetraacetate", J. Am. Chem. Soc., vol. 82, pp. 5342-5345, 1960.
Nielsen and Bundgaard, "Evaluation of Glycolamide Esters and Various Other Esters of Aspirin as True Aspirin Prodrugs", J. Medicinal Chem., vol. 32, pp. 727-734, 1989.
Nordenberg, et al., "Growth Inhibition of Murine Melanoma by Butyric Acid and Dimethylsulfoxide", Exp. Cell Res., vol. 162, pp. 77-85, 1986.
Nordenberg,, et al., "Biochemical and Ultrastructural Alterations Accompany the Anti-proliferative Effect of Butyrate on Melanoma Cells", Br. J. Cancer, vol. 55, pp. 493-497, 1987.
Novogrodsky, et al., "Effect of Polar Organic Compounds on Leukemic Cells", Cancer, vol. 51, No. 1, pp. 9-14, 1983.
Nudelman, et al., "Novel Anticancer Prodrugs of Butyric Acid", J. Med. Chem., vol. 35, pp. 687-694, 1992.
Oh, et al., "Convenient Synthesis of Geminal Biscarboxylates:Searching for an Efficient Route to HR 916B", Korean J. Med. Chem., vol. 6, No. 2, pp. 259-262, 1996.
Prasad, "Butyric Acid; A Small Fatty Acid with Diverse Biological Functions", Life Sci., vol. 27, No. 15, pp. 1351-1358, 1980.
Prasad, et al., "Decreased Expressions of c-myc and H-ras Oncogenes in Vitamin E Succinate Induced Morphologically Differentiated Murine B-16 Melanoma Cells in Culture", Biochem. Cell Bio., vol. 68, No. 11, pp. 1250-1255, 1990.
Rabizadeh, et al., "Rapid Alteration of c-myc and c-jun Expression in Leukemic Cells Induced to Differentiate By a Butyric Acid Prodrug", FEBS Lett., vol. 328, No. 3, pp. 225-229, 1993.
Rephaeli, et al., "Butyrate-Induced Differentiation in Leukemic Myeloid Cells: in vitro and in vivo Studies", International Journal of Oncology, vol. 4, No. 6, pp. 1387-1391, 1994.
Riggs, et al., "n-Butyrate Causes Histone Modification in HeLa and Friend Erythroleukaemia Cells", Nature, vol. 268, No. 5617, pp. 462-464, 1977.
Safadi, et al, "Phosphoryloxymethyl Carbamates and Carbonates- Novel Water-Soluble Prodrugs for Amines and Hindered Alcohols", Pharm. Res., vol. 10, No. 9, pp. 1350-1355, 1993.
Sagawa, et al., "Agricultural Chemicals Based on Dialkyl Halomethyl Phosphates for Killing Insects, Worms and Bacteria", Chem. Abstracts, vol. 78, Abstract #132708g, 1973.
Samid, et al., "Phenylacetate: A Novel Nontoxic Inducer of Tumor Cell Differentiation", Cancer Res., vol, 52, No. 7, pp. 1988-1992, 1992.
Sher, et al., "Extended Therapy with Intravenous Arginine Butyrate in Patients with Beta-Hemoglobinopathies", New England Journal of Medicine, vol. 332, No. 24, pp. 1606-1610, 1995.
Smigel, "Nontoxic Drug Being Tested to Treat Cancer and Anemias", J. Nat'l Cancer Inst., vol. 84, No. 18, pp. 1398-1399, 1992.
Smith, et al., "Incorporation of Tributyrin Enhances the Expression of a Reporter Gene in Primary and Immortalized Cell Lines", Biotechniques, vol. 18, No. 5, pp. 8

Affiliated with

Also associated with

Rating

Oxyalkylene phosphate compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oxyalkylene phosphate compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxyalkylene phosphate compounds and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-683134